38077-69-9

Basic information

• Product Name: 1-hydroxynaphthalene-2-carbonyl chloride
• Synonyms: 1-hydroxynaphthalene-2-carbonyl chloride;2-Naphthalenecarbonyl chloride, 1-hydroxy-
• CAS NO: 38077-69-9
• Molecular Formula: C₁₁H₇ClO₂
• Molecular Weight: 206.63
• Mol File: 38077-69-9.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-hydroxynaphthalene-2-carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-hydroxynaphthalene-2-carbonyl chloride(38077-69-9)
• EPA Substance Registry System: 1-hydroxynaphthalene-2-carbonyl chloride(38077-69-9)

Safety Data

• Hazardous Substances Data: 38077-69-9(Hazardous Substances Data)

Usage

Carbonyl chloride derivative

1-hydroxynaphthalene-2-carbonyl chloride is derived from 1-hydroxy-2-naphthoic acid by replacing the carboxyl group (-COOH) with a chlorine atom, forming a carbonyl chloride group (-CCl).

Reactivity

1-hydroxynaphthalene-2-carbonyl chloride is a reactive chemical reagent, which allows it to participate in various chemical reactions and form a wide range of organic molecules.

Versatility

This compound can be used in the preparation of diverse chemical compounds and pharmaceuticals, making it a valuable building block in organic synthesis.

Pharmaceutical industry application

1-hydroxynaphthalene-2-carbonyl chloride is commonly used as an intermediate in the synthesis of various pharmaceutical compounds.

Potential use in bioactive molecules

This compound is known for its potential use in the synthesis of bioactive molecules, which can have various biological effects and applications in medicine.

Key reagent in organic synthesis

Due to its reactivity and versatility, 1-hydroxynaphthalene-2-carbonyl chloride can be employed as a key reagent in the synthesis of a variety of organic compounds.

Upstream product

• 86-48-6 1-hydroxy-2-naphthoic acid 
• 18396-51-5 1-hydroxynaphthalene-2-carboxylic acid sodium salt 
• 10026-13-8 phosphorus pentachloride 

Downstream Products

• 948-03-8 1-hydroxy-naphthalene-2-carboxylic acid methyl ester 
• 115605-85-1 1-hydroxy-[2]naphthoic acid-([1]naphthyl-phenyl-amide) 
• 115605-51-1 1-hydroxy-[2]naphthoic acid-([2]naphthyl-phenyl-amide) 
• 62353-80-4 1-hydroxy-2-naphthalenecarboxamide 
• 109091-36-3 1-hydroxy-[2]naphthoic acid-(4-hydroxy-anilide) 
• 26675-52-5 1-hydroxy-N-(2-methoxyphenyl)naphthalene-2-carboxamide 
• 108478-69-9 1-hydroxy-[2]naphthoic acid-(4-acetyl-anilide) 
• 26639-36-1 1-hydroxy-N, N-diphenyl-2-naphthamide 
• 13545-65-8 1-hydroxynaphthalene-2-carboxanilide 
• 109883-65-0 N-(4-ethoxyphenyl)-1-hydroxynaphthalene-2-carboxamide 
• 110677-80-0 1-hydroxy-N-(3-methylphenyl)naphthalene-2-carboxamide 
• 26639-37-2 N-(2-ethoxyphenyl)-1-hydroxynaphthalene-2-carboxamide 
• 110677-77-5 1-hydroxy-N-(2-methylphenyl)naphthalene-2-carboxamide 
• 109812-63-7 1-hydroxy-N-methyl-N-phenyl-2-naphthamide 

Relevant articles and documents

-

-

Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques

The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of melanoma patients has driven the development of highly potent small inhibitors (BRAFi) of the mutated protein. To date, Dabrafenib and Vemurafenib, two specifi

Novel TypeII Fatty Acid Biosynthesis (FAS II) Inhibitors as Multistage Antimalarial Agents

Malaria is a potentially fatal disease caused by Plasmodium parasites and poses a major medical risk in large parts of the world. The development of new, affordable antimalarial drugs is of vital importance as there are increasing reports of resistance to the currently available therapeutics. In addition, most of the current drugs used for chemoprophylaxis merely act on parasites already replicating in the blood. At this point, a patient might already be suffering from the symptoms associated with the disease and could additionally be infectious to an Anopheles mosquito. These insects act as a vector, subsequently spreading the disease to other humans. In order to cure not only malaria but prevent transmission as well, a drug must target both the blood- and pre-erythrocytic liver stages of the parasite. P.falciparum (Pf) enoyl acyl carrier protein (ACP) reductase (ENR) is a key enzyme of plasmodial typeII fatty acid biosynthesis (FASII). It has been shown to be essential for liver-stage development of Plasmodium berghei and is therefore qualified as a target for true causal chemoprophylaxis. Using virtual screening based on two crystal structures of PfENR, we identified a structurally novel class of FAS inhibitors. Subsequent chemical optimization yielded two compounds that are effective against multiple stages of the malaria parasite. These two most promising derivatives were found to inhibit blood-stage parasite growth with IC50 values of 1.7 and 3.0μM and lead to a more prominent developmental attenuation of liver-stage parasites than the gold-standard drug, primaquine.